GKOS Stock Overview
An ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Glaukos Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$141.44 |
| 52 Week High | US$145.84 |
| 52 Week Low | US$59.22 |
| Beta | 1.03 |
| 11 Month Change | 6.80% |
| 3 Month Change | 8.75% |
| 1 Year Change | 124.33% |
| 33 Year Change | 191.39% |
| 5 Year Change | 122.01% |
| Change since IPO | 353.04% |
Recent News & Updates
Recent updates
Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?
Sep 18
Glaukos Corporation: Ripe For Some Consolidation
Sep 11Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 28Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 07Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear
Jul 18Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt
Jun 11Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun
May 30Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns
May 24Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching
Apr 22Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing
Apr 04Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price
Feb 21Is Glaukos (NYSE:GKOS) A Risky Investment?
Jan 21Glaukos: Remains A Hold Due To High Valuation And Negative Profitability
Jan 09Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors
Dec 20Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching
Nov 03Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?
Oct 05Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support
Sep 01Is Glaukos (NYSE:GKOS) Using Debt Sensibly?
Jun 28Glaukos: Revising To Buy On These 3 Catalytic Factors
Jun 16Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)
Apr 19Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?
Feb 19Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through
Feb 14Glaukos sees positive data from mid-stage trial of dry eye treatment
Jan 10Glaukos: Show Me The Money
Nov 10Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?
Oct 16Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80
Aug 24Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision
Aug 04Shareholder Returns
| GKOS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.3% | -0.4% | -1.0% |
| 1Y | 124.3% | 20.3% | 30.3% |
Return vs Industry: GKOS exceeded the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: GKOS exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| GKOS volatility | |
|---|---|
| GKOS Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GKOS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GKOS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 907 | Tom Burns | www.glaukos.com |
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Glaukos Corporation Fundamentals Summary
| GKOS fundamental statistics | |
|---|---|
| Market cap | US$7.95b |
| Earnings (TTM) | -US$149.57m |
| Revenue (TTM) | US$360.35m |
21.6x
P/S Ratio-52.1x
P/E RatioIs GKOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GKOS income statement (TTM) | |
|---|---|
| Revenue | US$360.35m |
| Cost of Revenue | US$84.28m |
| Gross Profit | US$276.06m |
| Other Expenses | US$425.64m |
| Earnings | -US$149.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.71 |
| Gross Margin | 76.61% |
| Net Profit Margin | -41.51% |
| Debt/Equity Ratio | 8.5% |
How did GKOS perform over the long term?
See historical performance and comparison